Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections
- PMID: 25371514
- DOI: 10.1093/cid/ciu593
Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections
Abstract
Background: Minocycline is an "old-drug" with Food and Drug Administration approval for the treatment of infection due to Acinetobacter species. The purpose of this study is to describe an Antimicrobial Stewardship Program's evaluation of minocycline for the treatment of patients with multidrug resistant A. baumannii (MDR-AB) infections.
Methods: This study evaluated hospitalized adult patients (September 2010 through March 2013) who received minocycline intravenously (IV) for a MDR-AB infection. Clinical and microbiological outcomes were analyzed. Secondary outcomes included infection-related mortality, length of hospital stay (LOS), infection-related LOS, intensive care unit (ICU) LOS, mechanical ventilation days, and 30-day readmission.
Results: A total of 55 patients received minocycline. Median age was 56 (23-85) years, 65% were male with an APACHE II score of 21 (4-41). Clinical success was achieved in 40/55 (73%) patients treated with minocycline monotherapy (n = 3) or in combination with a second active agent (n = 52). Overall 43 (78%) patients demonstrated documented or presumed microbiologic eradication. Infection-related mortality was 25%. Hospital LOS was 31 (5-132) and infection-related LOS was 16 (2-43) days. Forty-seven (85%) patients were admitted to the ICU for a LOS of 18 (2-78) days. Thirty-nine (71%) patients required mechanical ventilation for 6 (2-29) days. One patient had a 30-day readmission.
Conclusions: The response rate to minocycline monotherapy or in combination for the treatment of MDR-AB infections is encouraging as therapeutic options are limited. Prospective studies in patients with MDR-AB infections will help establish the role of minocycline alone or in combination with other antimicrobials.
Keywords: Acinetobacter baumannii; antimicrobial stewardship; minocycline.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Is minocycline a solution for multidrug-resistant Acinetobacter baumannii?Future Microbiol. 2014;9(3):299-305. doi: 10.2217/fmb.13.167. Future Microbiol. 2014. PMID: 24762305 Review.
-
Minocycline: an old drug for a new bug: multidrug-resistant Acinetobacter baumannii.Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S365-6. doi: 10.1093/cid/ciu531. Clin Infect Dis. 2014. PMID: 25371511 No abstract available.
-
Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.Int J Antimicrob Agents. 2014 Apr;43(4):378-82. doi: 10.1016/j.ijantimicag.2014.01.016. Epub 2014 Feb 14. Int J Antimicrob Agents. 2014. PMID: 24613422
-
Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.Ann Pharmacother. 2006 Nov;40(11):1939-45. doi: 10.1345/aph.1H353. Epub 2006 Oct 3. Ann Pharmacother. 2006. PMID: 17018688
-
Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.Int J Antimicrob Agents. 2016 Feb;47(2):107-16. doi: 10.1016/j.ijantimicag.2015.11.011. Epub 2015 Dec 13. Int J Antimicrob Agents. 2016. PMID: 26742726 Review.
Cited by
-
Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.Curr Infect Dis Rep. 2019 Nov 16;21(12):46. doi: 10.1007/s11908-019-0706-5. Curr Infect Dis Rep. 2019. PMID: 31734740 Review.
-
Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02371-16. doi: 10.1128/AAC.02371-16. Print 2017 May. Antimicrob Agents Chemother. 2017. PMID: 28264853 Free PMC article.
-
In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii.Antimicrob Agents Chemother. 2016 Jun 20;60(7):4047-54. doi: 10.1128/AAC.02994-15. Print 2016 Jul. Antimicrob Agents Chemother. 2016. PMID: 27114274 Free PMC article.
-
Antimicrobial Stewardship Programs: A Review of Strategies to Avoid Polymyxins and Carbapenems Misuse in Low Middle-Income Countries.Antibiotics (Basel). 2022 Mar 12;11(3):378. doi: 10.3390/antibiotics11030378. Antibiotics (Basel). 2022. PMID: 35326841 Free PMC article. Review.
-
Correlation of Checkerboard Synergy Testing with Time-Kill Analysis and Clinical Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Respiratory Infections.Antimicrob Agents Chemother. 2016 Oct 21;60(11):6892-6895. doi: 10.1128/AAC.00981-16. Print 2016 Nov. Antimicrob Agents Chemother. 2016. PMID: 27527089 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials